UMI-77, a selective MCL-1 inhibitor did not reduce B-ALL cell viability either alone or in combination with trametinib (Supplementary Table S3; Supplementary Figure S3a). Here, MCL1 is linked to precursor B-cell acute lymphoblastic leukemia.